Adam Boxer, MD, PhD
Adam L. Boxer, MD, PhD is the Endowed Professor in Memory and Aging in the Department of Neurology, Weill Institute of Neuroscience, University of California, San Francisco (UCSF). He received his MD and PhD from the New York University Medical Center Medical Scientist Training Program, completed a Neurology Residency at Stanford and a Neurobehavior Fellowship at UCSF. Dr. Boxer directs the Neurosciences Clinical Research Unit and the Alzheimer’s Disease and Frontotemporal Degeneration (FTD) Clinical Trials Program at the UCSF Memory and Aging Center. He is the Principal Investigator of the Alzheimer’s Disease Tau Platform clinical trial. He is co-Principal Investigator of the ARTFL/LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) project, a 27 site research network focused on preparing for FTD clinical trials, and the FTD Prevention Initiative (FPI), a global collaboration focused on preparing for prevention trials in autosomal dominant FTLD. He is PI of the Neurofilament Surveillance Project (NSP) that is developing blood biomarkers for use in FTLD clinical trials. He also leads the Four Repeat Tauopathy Neuroimaging Initiative (4RTNI), a multicenter, longitudinal biomarker study focused on PSP and CBD. He is organizing PI for Biomarker Evaluation in Young Onset Dementia from Diverse Populations (BEYONDD), a novel biomarker study working to understand the etiologies of early onset dementia in Black/African American and Latino/a/x individuals. He has been the PI for a variety of multicenter, randomized, placebo controlled clinical trials in neurodegenerative diseases, including memantine for FTLD, davunetide for PSP, TPI-287 for tauopathies, a Phase 1b trial of gosuranemab for PSP, and salsalate for AD and PSP. He is the lead PI of the planned NIH Alzheimer’s Clinical Trial Consortium’s (ACTC) Tau Platform clinical trial (ATP) as well as a planned PSP Platform Trial. He co-chaired the National Alzheimer’s Project Act (NAPA) FTLD Research Recommendations Committee in 2019 and 2022. He was founding co-chair of the FTLD Research Roundtable and co-chairs the PSP Research Roundtable, academic-industry collaborative groups working to speed the development of new therapies for FTLD, CBD and PSP.